$1.4M
6 filings since 2024 · latest Equity filed
NOK Therapeutics is a clinical-stage biotechnology company developing autologous natural killer (NK) cell immunotherapies for cancer. Its cells are drawn from the patient, expanded, and returned without genetic modification, and are given without the lymphodepleting chemotherapy that CAR-T and allogeneic cell therapies require. That allows outpatient infusion and repeat dosing, which the company positions at elderly, frail and heavily pre-treated patients who are excluded from existing cell therapies. Lead programs target multiple myeloma, where Phase 1 data were published in Cell Reports Medicine, and bladder cancer.
What sets it apart
A genetically unmodified, autologous NK cell therapy given without lymphodepletion, which removes the harsh pre-conditioning, hospital stay and toxicity that gate CAR-T access, and makes outpatient administration with flexible re-dosing practical.
A cell therapy platform that harvests a patient's own natural killer cells, expands them ex vivo without genetic engineering, and re-infuses them to restore immune defense against cancer, notably as consolidation after autologous stem cell transplant in multiple myeloma.
